Clinical and molecular epidemiology of malignant salivary gland tumors

• Published in: Laryngo- rhino- otologie Vol. 104; no. 2; p. 87
• Main Authors: Jansen, Louis, Nachtsheim, Lisa, Mayer, Marcel, Arolt, Christoph, Quaas, Alexander, Klußmann, Jens Peter, Wolber, Philipp
• Format: Journal Article
• Language: German; Spanish
• Published: Germany 01.02.2025
• Subjects: Humans; Prognosis; Risk Factors; Salivary Gland Neoplasms - epidemiology; Salivary Gland Neoplasms - genetics; Salivary Gland Neoplasms - mortality; Salivary Gland Neoplasms - pathology; Salivary Gland Neoplasms - therapy
• ISSN: 1438-8685
• DOI: 10.1055/a-2373-5741

Salivary gland carcinomas are a rare and heterogeneous group of malignant tumors, accounting for 3-6% of all malignant tumors in the head and neck region. The 1-, 3- and 5-year survival rates are 83%, 69% and 63% respectively. Due to new molecular pathological and genetic findings, new entities are constantly being defined as part of the recurring WHO classification of salivary gland carcinomas, so that the incidence rates of the entities are subject to constant change. The only certain risk factor for the development of salivary gland carcinomas is ionizing radiation. In addition, large tumors, cervical lymph node involvement and perineural sheath involvement significantly worsen the prognosis. Today, molecular pathology is coming to the fore, with which potential targets have been identified that can offer prognosis-improving treatment options, particularly in recurrent or distant metastatic stages. Entity-specific tyrosine kinase inhibitors such as axitinib in adenoid cystic carcinoma or larotrectinib in secretory carcinoma and cross-entity therapies such as HER2 inhibition and androgen deprivation can prolong median and progression-free survival with a favorable side effect profile.